Apitope Technology (Bristol) Ltd.

Quick facts

Phase 2 pipeline

• ATX-MS-1467 · Immunology
  ATX-MS-1467 is a peptide-based immunotherapy targeting myelin-associated glycoprotein (MAG) to treat multiple sclerosis.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Apitope Technology (Bristol) Ltd. portfolio CI brief
• Apitope Technology (Bristol) Ltd. pipeline updates RSS